Candel Therapeutics, Inc. engages in the development immunotherapies for the cancer patients.The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer. CAN-3110, in Phase I clinical trials for the. treatment of recurrent glioblastoma, has completed Phase Ib/II clinical trials.